The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001045303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/07/2026
Date registered
Help: Date registered
25/08/2026
Date last updated
Help: Date last updated
9/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
25/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study comparing two intravenous treatments, magnesium sulfate and aminophylline, to see which works better for children experiencing a severe asthma attack.
Scientific title
A randomised double-blind phase III effectiveness trial comparing intravenous magnesium sulfate to intravenous aminophylline for children with acute severe asthma (MAGIC study)
Additional trial identifiers [1] 317780 0
MRFF GNT MRF2044245
Universal Trial Number (UTN)
Trial acronym
MAGIC
Related trial records

Health condition
Health condition(s) studied:
Asthma 342684 0
Acute severe asthma 342687 0
Condition category
Condition code
Emergency medicine 338826 338826 0 0
Other emergency care
Respiratory 338827 338827 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Drug name: Intravenous magnesium sulfate (MgSO4)
Children receive intravenous magnesium sulfate (MgSO4), an IV bronchodilator used when inhaled treatments are insufficient for acute severe asthma. The dose is 0.2 mmol/kg (50 mg/kg), maximum 10 mmol, diluted to 50 mL and administered as a 30-minute IV infusion (0.4 mL/kg) via a standard Emergency Department IV line. The medication (International Non-proprietary Name: magnesium sulfate) is supplied in blinded 20 mL vials labelled MAGIC study medication A or MAGIC study medication B.

A single infusion is given at randomisation. If further parenteral bronchodilator treatment is required while the child remains in the Emergency Department, they receive the alternate blinded medication (aminophylline). No dose titration or individual tailoring occurs. If the child has left the Emergency Department when additional treatment is needed, subsequent parenteral therapy is determined by the treating clinical team.

Drug name: Intravenous aminophylline
Children receive intravenous aminophylline (International Non-proprietary Name: aminophylline) as an IV bronchodilator when inhaled therapy is insufficient. The dose is 10 mg/kg, maximum 500 mg, diluted to 50 mL and administered as a 30-minute IV infusion (0.4 mL/kg) via a standard Emergency Department IV line. The medication is supplied in blinded 20 mL vials labelled MAGIC study medication A or MAGIC study medication B.

A single infusion is given at randomisation. If further parenteral bronchodilator treatment is required while the child remains in the Emergency Department, they receive the alternate blinded medication (magnesium sulfate). As above, no dose titration occurs, and any additional treatment after leaving the Emergency Department is determined by the treating clinical team.

Both medications are supplied in identical blinded vials and prepared using the same dilution and infusion procedure to maintain blinding. Emergency Department clinicians administer all infusions according to a standardised protocol, and drug accountability logs and monitoring procedures are used to ensure adherence.
Intervention code [1] 334623 0
Treatment: Drugs
Description of the comparator or control
Intravenous aminophylline (International Non-proprietary Name: aminophylline) will be used as the comparator. Although both magnesium sulfate (MgSO4) and aminophylline are active agents, aminophylline represents the standard IV bronchodilator therapy against which IV magnesium sulfate is compared.

INN - Aminophylline

Dose - 10 mg/kg (maximum 500 mg)

Duration of treatment - Single intravenous infusion administered over 30 minutes. Further doses may be given only if clinically required and while the child remains in the Emergency Department, according to the protocol's blinded second medication procedure.

Mode of delivery - Intravenous infusion. Supplied in blinded 20 mL vials labelled “MAGIC study medication B”, diluted to 50 mL, and administered as 0.4 mL/kg over 30 minutes.

Adherence - Administration is fully supervised by clinical staff in the Emergency Department. Adherence is ensured through direct observation, protocol-mandated documentation, and drug accountability procedures.

Aminophylline will serve as the active control, delivered as intravenous bronchodilator therapy.
Control group
Active

Outcomes
Primary outcome [1] 346032 0
The primary outcome is a composite of (a) need for further parenteral bronchodilator treatment or (b) need for increased respiratory support by 4 hours post randomisation.
Timepoint [1] 346032 0
4 hours post-randomisation (primary timepoint)
Secondary outcome [1] 464361 0
Hospital length of stay (key secondary outcome)
Timepoint [1] 464361 0
From randomisation until hospital discharge.
Secondary outcome [2] 464362 0
Emergency Department length of stay
Timepoint [2] 464362 0
From ED arrival to ED discharge.
Secondary outcome [3] 464363 0
Hospital admission
Timepoint [3] 464363 0
At ED discharge decision.
Secondary outcome [4] 464364 0
Intensive care unit (ICU) admission;
Timepoint [4] 464364 0
Any time during hospitalisation.
Secondary outcome [5] 464365 0
ICU length of stay
Timepoint [5] 464365 0
From ICU admission to ICU discharge
Secondary outcome [6] 464366 0
Paediatric Respiratory Assessment Measure (PRAM) score at 2 and 4 hours after randomisation
Timepoint [6] 464366 0
2 hours post-randomisation and 4 hours post-randomisation
Secondary outcome [7] 464367 0
Proportion of participants with a Paediatric Respiratory Assessment Measure (PRAM) score greater than or equal to 3 points lower than the score at enrolment (baseline)
Timepoint [7] 464367 0
Assessed after all participants have completed the 2-hour post-randomisation assessment and after all participants have completed the 4-hour post-randomisation assessment.
Secondary outcome [8] 464368 0
Proportion of participants for whom no further parenteral bronchodilator treatment is required and whose Paediatric Respiratory Assessment Measure (PRAM) score is greater than or equal to 3 points lower than the baseline score. This will be assessed as a composite secondary outcome.
Timepoint [8] 464368 0
Clinical records will be reviewed to determine whether further parenteral bronchodilator treatment was administered within 2 and 4 hours after randomisation. PRAM scores documented at baseline, 2 hours, and 4 hours will be used to identify participants meeting the greater than or equal to 3-point threshold. The proportion of participants meeting both criteria will be calculated at each timepoint.
Secondary outcome [9] 464369 0
Proportion of participants for whom no further parenteral bronchodilator treatment is administered at 2 hours and 4 hours after randomisation, and at any stage during admission.
Timepoint [9] 464369 0
Clinical records will be reviewed to determine whether further parenteral bronchodilator treatment was administered within 2 and 4 hours after randomisation. PRAM scores documented at baseline, 2 hours, and 4 hours will be used to identify participants meeting the greater than or equal to 3-point threshold. The proportion of participants meeting both criteria will be calculated at each timepoint.
Secondary outcome [10] 464370 0
Use of respiratory support - Includes low-flow oxygen, high-flow nasal oxygen, non-invasive ventilation, mechanical ventilation.
Timepoint [10] 464370 0
The use of respiratory support will be recorded as a categorical outcome at baseline, 2 hours and 4 hours after randomisation, and at any stage during admission.
Secondary outcome [11] 464371 0
Time from randomisation until “ready for discharge”
Timepoint [11] 464371 0
Readiness for discharge will be defined as the earliest of (1) a composite outcome of (a) oxygen requirement at baseline and (b) inhaled bronchodilator therapy being administered no more than every 3 hours, or (2) the time of hospital discharge
Secondary outcome [12] 464372 0
Adverse effects (AE) - Includes nausea, vomiting, tremor, arrhythmia, palpitations, seizures, hypotension, electrolyte disturbances, ECG changes, decrease in reflexes.
Timepoint [12] 464372 0
Experienced within 2 hours post-randomisation; 4 hours post-randomisation and any time during admission
Secondary outcome [13] 464373 0
Additional treatment required for asthma - inhaled bronchodilators
Timepoint [13] 464373 0
Within 2 hours post-randomisation; 4 hours post-randomisation and any time during admission
Secondary outcome [14] 464374 0
Serious adverse events (SAEs)Serious adverse events include: - Endotracheal intubation - Cardiac arrest - Death
Timepoint [14] 464374 0
Within 2 hours post-randomisation; 4 hours post-randomisation and any time during admission
Secondary outcome [15] 464375 0
Parent / caregiver impression of work of breathing. Caregiver report (better / worse / same)
Timepoint [15] 464375 0
1 month post-discharge (censored at 6 weeks for prolonged admissions).
Secondary outcome [16] 464379 0
Incremental treatment cost
Timepoint [16] 464379 0
1 month post-discharge (censored at 6 weeks).
Secondary outcome [17] 464380 0
Caregiver time off work (Health economic outcome 2)
Timepoint [17] 464380 0
1 month post-discharge (censored at 6 weeks).
Secondary outcome [18] 464381 0
Participant time off school/pre-school (Health economic outcome 3)
Timepoint [18] 464381 0
1 month post-discharge (censored at 6 weeks).
Secondary outcome [19] 464382 0
Quality of life (Health economic outcome 4) at 1 month post-discharge
Timepoint [19] 464382 0
1 month post-discharge (censored at 6 weeks).
Secondary outcome [20] 464383 0
Asthma control
Timepoint [20] 464383 0
1 month post hospital discharge (censored at 6 weeks) after hospital discharge.
Secondary outcome [21] 465540 0
Additional treatment required for asthma - corticosteroids
Timepoint [21] 465540 0
Within 2 hours post-randomisation, 4 hours post-randomisation and anytime during admission
Secondary outcome [22] 465541 0
Additional treatment required for asthma - IV treatment.
Timepoint [22] 465541 0
Within 2-hours post randomisation, 4-hours post randomisation and any time during admission.
Secondary outcome [23] 465542 0
Additional treatment required for asthma - respiratory support
Timepoint [23] 465542 0
Within 2 hours post-randomisation, 4-hours post-randomisation and anytime during admission
Secondary outcome [24] 465543 0
Management of AEs - antiemetics
Timepoint [24] 465543 0
Within 2 hours post-randomisation, 4-hours post-randomisation and anytime during admission.
Secondary outcome [25] 465547 0
management of AEs- antiarrhythmics
Timepoint [25] 465547 0
Within 2 hours post-randomisation, 4-hours post-randomisation and anytime during admission
Secondary outcome [26] 465550 0
Management of AEs - IV Fluids
Timepoint [26] 465550 0
Within 2 hours post-randomisation, 4-hours post-randomisation and anytime during admission
Secondary outcome [27] 465554 0
Use of corticosteroids
Timepoint [27] 465554 0
1 month post hospital discharge (censored at 6 weeks) after hospital discharge.
Secondary outcome [28] 465555 0
Healthcare visits relating to asthma
Timepoint [28] 465555 0
1 month post hospital discharge (censored at 6 weeks) after hospital discharge.
Secondary outcome [29] 466588 0
Use of respiratory support - low-flow oxygen
Timepoint [29] 466588 0
The use of respiratory support will be recorded as a categorical outcome at baseline, 2 hours and 4 hours after randomisation, and at any stage during admission.
Secondary outcome [30] 466589 0
Use of respiratory support - high-flow nasal oxygen
Timepoint [30] 466589 0
The use of respiratory support will be recorded as a categorical outcome at baseline, 2 hours and 4 hours after randomisation, and at any stage during admission.
Secondary outcome [31] 466590 0
Use of respiratory support - non-invasive ventilation
Timepoint [31] 466590 0
The use of respiratory support will be recorded as a categorical outcome at baseline, 2 hours and 4 hours after randomisation, and at any stage during admission.
Secondary outcome [32] 466591 0
Use of respiratory support - mechanical ventilation
Timepoint [32] 466591 0
The use of respiratory support will be recorded as a categorical outcome at baseline, 2 hours and 4 hours after randomisation, and at any stage during admission.

Eligibility
Key inclusion criteria
(i) child aged from 2 (2 years and 0 days) to 15 years (up to 15 years + 364 days);
(ii) receiving ED care for severe exacerbation of asthma / wheeze; and
(iii) ED-based treating clinical team determines that IV bronchodilator therapy is required; and
(iv) IV access is secured.
Minimum age
2 Years
Maximum age
15 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
(i) patient has already received IV bronchodilators (e.g. salbutamol, MgSO4 or aminophylline) for this exacerbation;
(ii) peri-arrest or requiring immediate non-invasive ventilation, where multiple parenteral therapies are planned simultaneously;
(iii) allergy to or contraindications to study medication;
(iv) suspected anaphylaxis;
(v) patient-specific ED management plan dictating choice of IV bronchodilator;
(vi) child is under care of child protection services;
(vii) child presents with parents/guardians who require an interpreter and an appropriate interpreter is not readily available; or
(viii) previous study enrolment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed. Pre-packed opaque trial boxes containing blinded study medication to be used.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Treatment allocations will be computer-generated using permuted block randomisation with variable sizes prepared by a statistician independent of the trial team. Randomisation will be stratified by site and age (=5 years, >5 years)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC
Recruitment outside Australia
Country [1] 28281 0
New Zealand
State/province [1] 28281 0

Funding & Sponsors
Funding source category [1] 322324 0
Government body
Name [1] 322324 0
NHMRC Medical Research Future Funds (MRFF): GNT2044245
Country [1] 322324 0
Australia
Funding source category [2] 322329 0
Government body
Name [2] 322329 0
NEW ZEALAND Health Research Council of New Zealand (HRC): 25/531
Country [2] 322329 0
New Zealand
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 325243 0
Government body
Name [1] 325243 0
NEW ZEALAND Health Research Council of New Zealand (HRC): 25/531
Address [1] 325243 0
Country [1] 325243 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320828 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 320828 0
Ethics committee country [1] 320828 0
Australia
Date submitted for ethics approval [1] 320828 0
01/07/2026
Approval date [1] 320828 0
15/07/2026
Ethics approval number [1] 320828 0
HREC/128187/MonH-2026-532333

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151770 0
Prof Simon Craig
Address 151770 0
Monash University, Department of Paediatrics Monash Children's Hospital Level 5, 246 Clayton Road, Clayton VIC 3168
Country 151770 0
Australia
Phone 151770 0
+61 3 9594 2707
Fax 151770 0
Email 151770 0
Contact person for public queries
Name 151771 0
Simon Craig
Address 151771 0
Monash University, Department of Paediatrics Monash Children's Hospital Level 5, 246 Clayton Road, Clayton VIC 3168
Country 151771 0
Australia
Phone 151771 0
+61 3 9594 2707
Fax 151771 0
Email 151771 0
Contact person for scientific queries
Name 151772 0
Simon Craig
Address 151772 0
Monash University, Department of Paediatrics Monash Children's Hospital Level 5, 246 Clayton Road, Clayton VIC 3168
Country 151772 0
Australia
Phone 151772 0
+61 3 9594 2707
Fax 151772 0
Email 151772 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
12 months after publication of results

To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected] or [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.